Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy | Zendy

C. Michael Gibson | Zendy; Duane S. Pinto | Zendy; Gerald Chi | Zendy; Douglas Arbetter | Zendy; Megan K. Yee | Zendy; Roxana Mehran | Zendy; Christoph Bode | Zendy; Jonathan L. Halperin | Zendy; Freek W.A. Verheugt | Zendy; Peter Wildgoose | Zendy; Paul Burton | Zendy; Martin van Eickels | Zendy; Serge Korjian | Zendy; Yazan Daaboul | Zendy; Purva Jain | Zendy; Gregory Y.H. Lip | Zendy; Marc Cohen | Zendy; Eric D. Peterson | Zendy; Keith A.A. Fox | Zendy

Open Access

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Author(s) -

C. Michael Gibson,

Duane S. Pinto,

Gerald Chi,

Douglas Arbetter,

Megan K. Yee,

Roxana Mehran,

Christoph Bode,

Jonathan L. Halperin,

Freek W.A. Verheugt,

Peter Wildgoose,

Paul Burton,

Martin van Eickels,

Serge Korjian,

Yazan Daaboul,

Purva Jain,

Gregory Y.H. Lip,

Marc Cohen,

Eric D. Peterson,

Keith A.A. Fox

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.025783

Subject(s) - medicine , rivaroxaban , atrial fibrillation , vitamin k antagonist , hazard ratio , confidence interval , clinical endpoint , cardiology , warfarin , randomized controlled trial

Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that a regimen of rivaroxaban plus a P2Y 12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby have a favorable impact on all-cause mortality and the need for rehospitalization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research